**Neonatal Fever v8.0: ED Phase (0-28 days old)**

**PHASE I (E.D.)**

**Inclusion Criteria**
- Fever ≥38°C (or a reliable history of fever) or hypothermia <36°C in children <28 days of age

**Exclusion Criteria**
- Patients currently admitted to ICU or admitted >3 days
- Known immunodeficiency or cancer
- Patients with central venous catheters or VP shunts

---

**Focal Infection**
(e.g., omphalitis, pneumonia)

- UA, urine culture
- CBC with diff, Blood culture
- CSF studies
- HSV work up if indicated (see box)
- CXR and respiratory viral panel (if respiratory symptoms)
- Stool PCR (if diarrhea)

---

**Inability to obtain CSF in ED**

- Administer antibiotics (GOAL: within 60 minutes)
- Refer to IR for lumbar puncture as inpatient
- Rapid CSF Bacterial PCR can be sent on pre-treated CSF that demonstrates pleocytosis

---

**HSV work up indications**
Perform complete work up and begin acyclovir for any of the following:

**Historical and clinical features**
- severe illness
- hypothermia
- lethargy
- seizures
- hepatosplenomegaly
- postnatal HSV contact
- vesicular rash
- conjunctivitis
- interstitial pneumonitis

**Laboratory features**
- thrombocytopenia
- CSF pleocytosis >20 WBC/mm³ without clear bacterial infection (e.g., + Gram stain)

---

**If CSF pleocytosis consider CSF Rapid Viral Qual, PCR**

---

**Other differential diagnosis for severely ill neonates**

---

**CSF Normative values**
0-1 month: CSF WBC <20/mm³
≥1 month: CSF WBC <10/mm³

---

For questions concerning this pathway, contact: NeonatalFever@seattlechildrens.org

© 2022 Seattle Children's Hospital, all rights reserved, Medical Disclaimer
Discharge Criteria (meets all)
- Eating well and well appearing
- No social/family concerns
- Reliable follow-up in 12-24 hours
- Outpatient plan accepted by PMD and family

Meets all low risk criteria?
- Yes: Go to Inpatient Phase (29-56d)
- No: Admit for observation
  - CSF studies and antibiotics if worsens

Inability to obtain CSF in ED
- Considerations for Pretreated CSF
  - Administer antibiotics (GOAL: within 60 minutes)
  - Refer to IR for lumbar puncture as inpatient
  - Rapid CSF Bacterial PCR can be sent on pre-treated CSF that demonstrates pleocytosis

Meets all low risk criteria?
- Yes: Go to Inpatient Phase (29-56d)
- No: Transfer to ED for additional work up and antibiotics

Ceftriaxone contraindicated with hyperbilirubinemia

Focal Infection (e.g., meningitis, pneumonia)

Focal Infection (e.g., meningitis, pneumonia)

CONSIDER NEONATAL FEVER 29-56 days W/BRONCH ED PHASE

Low Risk Criteria
- Well-appearing
- Previously healthy
- Full term (≥37 weeks)
- No focal bacterial infection
- Negative urinalysis
- WBC >5,000 and <15,000 mm$^3$
- Absolute bands <1,500 mm$^3$
- No discrete infiltrates on CXR if done

If CSF pleocytosis consider CSF Rapid Viral Qual. PCR

Urgent Care Transfer Guidelines (for 29-56 days)
- Ill appearing neonates with fever:
  - Initiate transport immediately
  - Attempt to obtain labs
  - Give antibiotics (IV or IM)

Does not meet low risk criteria:
- Transfer to ED for additional work up and antibiotics

Recurrence of fever:
- Initiate transport immediately
- Attempt to obtain labs
- Give antibiotics (IV or IM)

CSF Rapid Viral Qual. PCR

Inpatient Phase (29-56d)

Discharge Criteria (meets all)
- Eating well and well appearing
- No social/family concerns
- Reliable follow-up in 12-24 hours
- Outpatient plan accepted by PMD and family

Meets all low risk criteria?
- Yes: Go to Inpatient Phase (29-56d)
- No: Transfer to ED for additional work up and antibiotics

Ceftriaxone contraindicated with hyperbilirubinemia

Focal Infection (e.g., meningitis, pneumonia)

Focal Infection (e.g., meningitis, pneumonia)

CONSIDER NEONATAL FEVER 29-56 days W/BRONCH ED PHASE

Low Risk Criteria
- Well-appearing
- Previously healthy
- Full term (≥37 weeks)
- No focal bacterial infection
- Negative urinalysis
- WBC >5,000 and <15,000 mm$^3$
- Absolute bands <1,500 mm$^3$
- No discrete infiltrates on CXR if done

If CSF pleocytosis consider CSF Rapid Viral Qual. PCR

Urgent Care Transfer Guidelines (for 29-56 days)
- Ill appearing neonates with fever:
  - Initiate transport immediately
  - Attempt to obtain labs
  - Give antibiotics (IV or IM)

Does not meet low risk criteria:
- Transfer to ED for additional work up and antibiotics

Recurrence of fever:
- Initiate transport immediately
- Attempt to obtain labs
- Give antibiotics (IV or IM)

CSF Rapid Viral Qual. PCR

Inpatient Phase (29-56d)

Discharge Criteria (meets all)
- Eating well and well appearing
- No social/family concerns
- Reliable follow-up in 12-24 hours
- Outpatient plan accepted by PMD and family

Meets all low risk criteria?
- Yes: Go to Inpatient Phase (29-56d)
- No: Transfer to ED for additional work up and antibiotics

Ceftriaxone contraindicated with hyperbilirubinemia

Focal Infection (e.g., meningitis, pneumonia)

Focal Infection (e.g., meningitis, pneumonia)

CONSIDER NEONATAL FEVER 29-56 days W/BRONCH ED PHASE

Low Risk Criteria
- Well-appearing
- Previously healthy
- Full term (≥37 weeks)
- No focal bacterial infection
- Negative urinalysis
- WBC >5,000 and <15,000 mm$^3$
- Absolute bands <1,500 mm$^3$
- No discrete infiltrates on CXR if done

If CSF pleocytosis consider CSF Rapid Viral Qual. PCR

Urgent Care Transfer Guidelines (for 29-56 days)
- Ill appearing neonates with fever:
  - Initiate transport immediately
  - Attempt to obtain labs
  - Give antibiotics (IV or IM)

Does not meet low risk criteria:
- Transfer to ED for additional work up and antibiotics

Recurrence of fever:
- Initiate transport immediately
- Attempt to obtain labs
- Give antibiotics (IV or IM)

CSF Rapid Viral Qual. PCR

Inpatient Phase (29-56d)
Neonatal Fever v8.0: Inpatient Phase (0-28 days old)

PHASE II (INPATIENT)

Inclusion Criteria
• Fever ≥38°C (or a reliable history of fever) or hypothermia <36°C in children ≤28 days of age

Exclusion Criteria
• Patients currently admitted to ICU or admitted >3 days
• Known immunodeficiency or cancer
• Patients with central venous catheters or VP shunts

CSF Pleocytosis >20 WBC/mm³?

Yes
Ampicillin + Cefotaxime (or Ceftazidime if Cefotaxime unavailable)

No

Review Urinalysis results

Positive
Ampicillin + gentamicin

Negative
Cefotaxime Monotherapy (or Ceftazidime if Cefotaxime unavailable)

Further evaluation per primary team

Discharge Criteria (Meets all)
• Tolerating PO
• Well-appearing
• At 36 hours if cultures negative
• HSV discharge criteria
• Adequate follow-up
• PMD and family agree with plan

Inability to obtain CSF in ED
Considerations for Pretreated CSF
• ED administers antibiotics
• Refer to IR for lumbar puncture as inpatient
• Rapid CSF Bacterial PCR can be sent on pre-treated CSF that demonstrates pleocytosis

Neg. cultures

Daily re-evaluation

Improving and meets discharge criteria?

Yes

Discharge Instructions
• PMD f/u within 48-72 hours

No

When to discontinue acyclovir

Inability to obtain CSF in ED

Considerations for Pretreated CSF

! Consider discharge at 24 hours if non-HSV viral studies positive & patient well-appearing

! If CSF pleocytosis consider CSF Rapid Viral Qual. PCR

! If CSF pleocytosis consider CSF Rapid Viral Qual. PCR

For questions concerning this pathway, contact: NeonatalFever@seattlechildrens.org
© 2022 Seattle Children’s Hospital, all rights reserved, Medical Disclaimer

Last Updated: January 2022
Next Expected Review: January 2024

CSF Pleocytosis

Yes

No

When to discontinue acyclovir
PHASE I (E.D.)

Inclusion Criteria
- Fever ≥38°C (or a reliable history of fever) or hypothermia <36°C in children 29-56 days of age with signs of bronchiolitis

Exclusion Criteria
- Patients currently admitted to ICU or admitted >3 days
- Known immunodeficiency or cancer
- Patients with central venous catheters or VP shunts

Symptoms of Bronchiolitis:
(increased work of breathing, cough, tachypnea, wheezing)

Signs of poor perfusion or mental status changes or sepsis score > 3

YES → Continue workup per Neonatal Fever (29-56d) pathway

NO → Consider UA/Culture in patients who are persistently febrile or vomiting

UA +

Blood CX

Ceftriaxone

Admit to inpatient on UTI and Bronchiolitis pathway

UA – OR UA NOT INDICATED

Off Pathway

CONSIDER BRONCHIOLITIS PATHWAY

In patients presenting with fever and bronchiolitis, the risk of bacteremia and meningitis is low. UTI should be considered in patients who are persistently symptomatic with fever or vomiting.

Onset of NEW fever during hospitalization in patients with bronchiolitis can be indicative of a serious bacterial infection.
Neonatal Fever v8.0: Inpatient Phase (29-56 days old)

**Inclusion Criteria**
- Fever ≥38°C (or a reliable history of fever) or hypothermia <36°C in children 29-56 days of age

**Exclusion Criteria**
- Patients currently admitted to ICU or admitted >3 days
- Known immunodeficiency or cancer
- Patients with central venous catheters or VP shunts

**Daily re-evaluation**
- Positive cultures
  - Treat specific condition
  - Consider LP in patients with bacteremia if not done prior
  - Begin antibiotics if not begun prior; narrow antibiotic agent if possible
- Negative cultures
  - Improving and meets discharge criteria?
    - Yes
      - Discharge Instructions
        - PMD f/u within 48-72 hours
    - No
      - Further evaluation per primary team

**Discharge Criteria** (Meets all)
- Tolerating PO
- Well-appearing
- At 36 hours if cultures negative and antibiotics begun
- At 24 hours if cultures negative and no antibiotics begun
- Adequate follow-up
- PMD and family agree with plan

**Considerations for Pretreated CSF**
- Rapid CSF Bacterial PCR can be sent on pre-treated CSF that demonstrates pleocytosis

**Explanation of Evidence Ratings**

**Approval & Citation**

© 2022 Seattle Children’s Hospital, all rights reserved, Medical Disclaimer

For questions concerning this pathway, contact: NeonatalFever@seattlechildrens.org

Last Updated: January 2022
Next Expected Review: January 2024
Background

Fever is a common presenting symptom in neonates and young infants:

- 12-28% will have a serious bacterial infection (which include bacteremia/sepsis, bacterial gastroenteritis, cellulitis, osteomyelitis, septic arthritis, meningitis, pneumonia and urinary tract infection) (Source: Cincinnati Children’s Hospital; Fever of Uncertain Source Guideline)
  - UTI is the most common.
  - 0-1.2% of all febrile neonates will have bacterial meningitis
- 0.3% will have HSV (Caviness)

Because the clinical exam alone is unreliable to predict serious illness in this age group, clinicians must rely on a combination of history, physical exam and diagnostics tests to determine a patient’s risk of Serious Bacteria infection (SBI) and balance this risk with the cost and morbidity of empiric treatment.
**Introduction – Neonatal Fever**

This clinical standard work pathway is meant to guide the management of febrile neonates age 0-56 days in the Emergency Department and Inpatient Medical Unit.

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever =38 C (or a reliable history of fever)</td>
<td>Patients currently admitted to ICU or admitted &gt;3 days</td>
</tr>
<tr>
<td>Hypothermia &lt;36 C in children &lt;56 days of age</td>
<td>Known immunodeficiency or cancer</td>
</tr>
<tr>
<td></td>
<td>Patients with central venous catheters or VP shunts</td>
</tr>
</tbody>
</table>

Febrile neonates 0-56 days will enter on this Neonatal Fever pathway and may move to another CSW pathway, such as UTI, pneumonia or bronchiolitis when diagnosis is established.
Bacteremia and meningitis are uncommon in patients with bronchiolitis and/or RSV

Levine 2004: 1248 patients < 60 days, 269 (22% with RSV)
- Overall rate Levine of SBI = 11.4%
- Rate of SBI in RSV+ patients = 7% (all were UTIs, no bacteremia or meningitis)
- Rate of SBI in RSV– patients = 12.5%
- CONCLUSION: Febrile infants <60d who have RSV infections are at significantly lower risk of SBI than infants without RSV infection

Purcell 2002: 2396 patients, 285 (11.9%) < 6 weeks
- 12 + blood cultures, all deemed contaminants
- 27 + urine cultures

Oray-Schrom 2003: 191 infants with RSV age 0-90 days; complete sepsis work-up performed on 52.5% of febrile cohort
- 5 with UTI (7.2%)
- 1 with bacteremia (1.2%)
- None with meningitis (0%)

Risk of Serious Bacterial infections in patients with bronchiolitis and/or RSV

Bacteremia and meningitis are uncommon in patients with bronchiolitis and/or RSV

Purcell 2004: 912 patients with bronchiolitis
- 2 of 470 patients tested had positive blood culture (0.43%)
- 0 of 101 patients tested had positive CSF (0%)
- 28 of 234 patients tested had positive urine (12%)
- CONCLUSION: Routine sepsis and meningitis work-ups are not necessary in non-toxic appearing infants and young children with RSV lower respiratory tract infections.

Tsolia 2002: 636 infants < 12 months; blood and urine obtained on patients with fever >38 or ill appearing (174 patients)
- 0 positive blood cultures
- 8 positive urine cultures (4.6%)

Neonatal Fever (29-56d) w/Bronchiolitis ED
Hypothermia

Hypothermia

- Septic work-up should not be delayed in neonate with a rectal temperature of less than 36°C.
- Neonates should be able to maintain temperature stability when dressed in one layer of clothes more than adults and a hat.
  - If there is concern that low temperature is caused by environmental factors: swaddle, place a hat on the baby and have caregivers hold for 30 minutes. Re-check temperature. Low temperatures due to environmental factors should be resolved by these measures.
- Hypothermic babies are at higher risk for hypoglycemia. Consider checking a glucose level.
Other Exclusions: Focal Infection

Patients with clinical evidence of focal infections (e.g., omphalitis, pneumonia, cellulitis) are excluded from the neonatal fever pathway.

- These patients may still need to undergo a “febrile neonate” work-up
- Based on site of infection, empiric antibiotic choice may be different
Infants 0-28 Days: HSV – Complete HSV Work-up

Comprehensive testing for neonatal HSV infection should include:

- Surface swabs from nasopharynx and bi-lateral conjunctivae sent for HSV Rapid PCR (3 swabs pooled in one media)
  - These specimens will be collected by RN
- CSF for CSF Rapid Viral Qual. PCR
- Blood for HSV PCR Quant. blood
- Skin vesicle fluid for HSV Rapid PCR
  - Provider will unroof vesicle and swab lesion
- CBC with differential, BUN, creatinine, AST and ALT

Complete the work-up for HSV in the Emergency Department.
Infants 0-28 Days: Inpatient Management (Cont’d)

HSV

If positive for HSV, continue acyclovir and transfer to ID service.

If CSF Rapid HSV PCR positive, add on quantitative CSF HSV PCR

Discontinue Acyclovir when:

- If patient is **well-appearing and no evidence of HSV SEM disease**: negative surface and CSF Rapid PCRs (may consider discharge before blood HSV PCR result)
- If patient **has a definitive alternate diagnosis** (even if not well-appearing): negative surface and CSF Rapid PCRs
- If **high ongoing HSV suspicion**: wait for all HSV studies (surface/blood PCRs) to return negative

Discharge Criteria:

- Well-appearing
- Tolerating PO/enteral feeds
- At 36 hours all cultures negative
- Meets HSV discharge criteria, if applicable
- Follow-up available with 48-72 hours
- PMD and family agree with plan
Risk of Serious Bacterial infections in patients with bronchiolitis and/or RSV (Fever and Bronchiolitis)

Bacteremia and meningitis are uncommon in patients with bronchiolitis and/or RSV

Levine 2004: 1248 patients < 60 days, 269 (22% with RSV)
• Overall rate Levine of SBIs = 11.4%
• Rate of SBI in RSV+ patients = 7% (all were UTIs, no bacteremia or meningitis)
• Rate of SBI in RSV– patients = 12.5%
• CONCLUSION: Febrile infants <60d who have RSV infections are at significantly lower risk of SBIs than infants without RSV infection

Purcell 2002: 2396 patients, 285 (11.9%) < 6 weeks
• 12 + blood cultures, all deemed contaminants
• 27 + urine cultures

Oray-Schrom 2003: 191 infants with RSV age 0-90 days; complete sepsis work-up performed on 52.5% of febrile cohort
• 5 with UTI (7.2%)
• 1 with bacteremia (1.2%)
• None with meningitis (0%)
## Febrile Infants with bronchiolitis and/or RSV remain at risk for co-infection with UTI

<table>
<thead>
<tr>
<th>Author</th>
<th>Date</th>
<th>Rate of UTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levine</td>
<td>2004</td>
<td>5.4% (14/261)</td>
</tr>
<tr>
<td>Purcell</td>
<td>2004</td>
<td>14.9% (14/94)</td>
</tr>
<tr>
<td>Purcell</td>
<td>2002</td>
<td>27+ (unknown number collected—2396 in study)</td>
</tr>
<tr>
<td>Oray-Schrom</td>
<td>2003</td>
<td>7.2% (5/69)</td>
</tr>
<tr>
<td>Tsolia</td>
<td>2002</td>
<td>4.65 (8/174)</td>
</tr>
<tr>
<td>Randolph</td>
<td>2004</td>
<td>0.6% (1/121)</td>
</tr>
<tr>
<td>Titus</td>
<td>2003</td>
<td>1.3% (2/147)</td>
</tr>
</tbody>
</table>

Risk of UTI in patients with bronchiolitis and/or RSV ranges from 0.6% to 15%
RECOMMENDATIONS:

Febrile Infants **age 0-28 days** of age remain at risk for serious bacterial infections and should have a full sepsis work-up despite the presence or absence of bronchiolitis.

Febrile infants **age 29-56 days** who are non-toxic appearing (no symptoms of poor perfusion, acute mental status changes or significant tachycardia) and have clinical symptoms of bronchiolitis do not require a full sepsis workup. **Blood and CSF cultures are not routinely recommended in this population.**

Urinalysis and culture should be considered in patients age 29-56 days with persistent fever (2 or more occurrences), vomiting or excessive irritability.
Late Occurrence of Fever in Patients with Bronchiolitis

Patients with bronchiolitis and/or RSV who develop fever during hospitalization are at higher risk for serious bacterial infection and additional work-up should be considered.

Tsolia: 5 of 636 infants admitted with bronchiolitis subsequently acquired bacteremia during their hospitalization for bronchiolitis

Bloomfield demonstrated increased risk of bacteremia in patients with:
- Nosocomial RSV (OR= 23.4)
- PICU admission (OR = 9.4)
- Ventilatory support (OR=7.4)
- Cyanotic heart disease (OR 10.8)
Introduction – Neonatal Fever

This clinical standard work pathway is meant to guide the management of febrile neonates age 0-56 days in the Emergency Department and Inpatient Medical Unit.

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever =38 C (or a reliable history of fever)</td>
<td>Patients currently admitted to ICU or admitted &gt;3 days</td>
</tr>
<tr>
<td>Hypothermia &lt;36 C in children &lt;56 days of age</td>
<td>Known immunodeficiency or cancer</td>
</tr>
<tr>
<td></td>
<td>Patients with central venous catheters or VP shunts</td>
</tr>
</tbody>
</table>

Febrile neonates 0-56 days will enter on this Neonatal Fever pathway and may move to another CSW pathway, such as UTI, pneumonia or bronchiolitis when diagnosis is established.
Other Exclusions: Focal Infection

Patients with clinical evidence of focal infections (e.g., omphalitis, pneumonia, cellulitis) are excluded from the neonatal fever pathway.

- These patients may still need to undergo a “febrile neonate” work-up
- Based on site of infection, empiric antibiotic choice may be different
Infants 0-28 Days: Initial ED Workup

Testing for all patients should include:

- CBC with differential
- Blood culture
- UA, urine culture
- CSF studies (obtain 4 tubes)
  - If patient is clinically unstable, LP can be delayed and antibiotics should be administrated
- Respiratory viral panel for respiratory symptoms
- CXR for respiratory symptoms not consistent with bronchiolitis
- Stool PCR if diarrhea present
Patients 0-28 days who present with fever $= 38$ and symptoms of bronchiolitis should still have a full work-up that includes:

- CBC with differential
- Blood culture
- UA, urine culture
- CSF studies (obtain 4 tubes)
- Chest X-ray can be deferred if patient has clear clinical bronchiolitis (Local Consensus)
In addition to initial work-up, initiate HSV work-up on patients with ANY of the following:

<table>
<thead>
<tr>
<th>Historical and Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe Illness</td>
</tr>
<tr>
<td>Hypothermia</td>
</tr>
<tr>
<td>Lethargy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>CSF pleocytosis &gt;20 WBC/mm³ without clear bacterial infection (negative Gram stain)</td>
</tr>
<tr>
<td>Elevated LFTs</td>
</tr>
</tbody>
</table>

---

*Initial ED phase 0-28d*

*Initial ED phase 29-56d*

*Inpatient Phase 0-28d*

*Inpatient Phase 29-56d*
Infants at greatest risk of neonatal HSV are those born vaginally (especially with use of invasive monitoring or with history of leaking membranes prior to delivery) to mothers with any of the following risk factors for primary maternal HSV infection:

- Mother's current or past sex partners have a history of genital or oral HSV
- New sexual partner in pregnancy, especially late in gestation
- Sores in the vagina, or opening of the vagina, during pregnancy, especially bilaterally on the vulva late in gestation
- Urinary retention (sometimes misdiagnosed as an UTI)
- History of frequent yeast infections
- Receipt of oral sex during the last half of pregnancy from partner with history of cold sores

NOTE: These are maternal risk factors for primary HSV infection. Use clinical judgment in determining if HSV work up is indicated in well-appearing infants born to mothers with multiple risk factors.
Discharge Criteria:

- Well-appearing
- Tolerating PO/enteral feeds
- At 36 hours all cultures negative
- Meets HSV discharge criteria, if applicable
- Follow-up available with 48-72 hours
- PMD and family agree with plan
All patients should receive a single dose of ampicillin and cefotaxime immediately after appropriate cultures are obtained, without waiting for initial CSF counts:

- Rapid administration of appropriate antibiotics is associated with improved outcomes.
- Goal is for antibiotics to be administered within 60 minutes of presentation.
- Antibiotics can be narrowed by the admitting team once cell counts are available.

**NOTE:** Due to nationwide shortage of Cefotaxime, Ceftazidime should be given if Cefotaxime is unavailable.

**NOTE:** All patients with suspicion of HSV should receive acyclovir in addition to antibiotics.
Infants 0-28 Days: Inpatient Management

Admission Criteria
Recommend admission of all febrile neonates age 0-28 days for empiric antibiotics.
Antibiotic choice is based on concern for meningitis and risk for enterococcus and listeria:

<table>
<thead>
<tr>
<th>Concern for Meningitis</th>
<th>Concern for UTI</th>
<th>Antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>High ($\geq 20 \text{ WBC/mm}^3$)</td>
<td></td>
<td>Ampicillin and cefotaxime (or ceftazidime)</td>
</tr>
<tr>
<td>Low ($&lt; 20 \text{ WBC/mm}^3$)</td>
<td>Yes</td>
<td>Ampicillin and Gentamicin</td>
</tr>
<tr>
<td>Low ($&lt; 20 \text{ WBC/mm}^3$)</td>
<td>No</td>
<td>Cefotaxime (or ceftazidime)</td>
</tr>
</tbody>
</table>

Continue acyclovir for those with an HSV workup pending:

- Recommend 1.5x maintenance fluids to prevent renal tubular injury for patients on acyclovir
HSV

If positive for HSV, continue acyclovir and transfer to ID service.

If CSF Rapid HSV PCR positive, add on quantitative CSF HSV PCR

Discontinue Acyclovir when:

- **If patient is well-appearing and no evidence of HSV SEM disease:** negative surface and CSF Rapid PCRs (may consider discharge before blood HSV PCR result)
- **If patient has a definitive alternate diagnosis** (even if not well-appearing): negative surface and CSF Rapid PCRs
- **If high ongoing HSV suspicion:** wait for all HSV studies (surface/blood PCRs) to return negative
Discharge Criteria:

- Well-appearing
- Tolerating PO/enteral feeds
- At 36 hours all cultures negative
- Meets HSV discharge criteria, if applicable
- Follow-up available with 48-72 hours
- PMD and family agree with plan
Evidence: All Age Groups

Inpatient discharge at 36 hours:

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Seattle Children’s 2012 Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approximately 90% of bacterial pathogens are identified within the first 24 hours of incubation. (Cincinnati)</td>
<td>Total of 41 patients &lt;61 days of age with a positive blood culture (including NICU).</td>
</tr>
<tr>
<td>In blood cultures of infants age 0-6 months:</td>
<td>Of the 41, 7 patients, or 14%, had their first culture turn positive after 36 hours.</td>
</tr>
<tr>
<td>• Mean time to positivity for true pathogens is approximately 17.5 hours.</td>
<td>Of the 7, only one qualified for the fever pathway and that child was identified with a UTI and treated appropriately</td>
</tr>
<tr>
<td>• Median time to positivity for urine and CSF cultures are 16 and 18 hours, respectively. (Cincinnati; Byington)</td>
<td></td>
</tr>
</tbody>
</table>

Initial ED phase 0-28d

Initial ED phase 29-56d

Inpatient Phase 0-28d

Inpatient Phase 29-56d
Evidence: All Age Groups (Cont’d)

Inpatient discharge at 36 hours: (Cont’d)

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2190 patients with all 3 cultures (Blood/CSF/Urine):</td>
</tr>
<tr>
<td>• 28 positive blood culture: median time to positivity 16 hours (6-50)</td>
</tr>
<tr>
<td>• 8 positive CSF cultures: median time to positivity 18 hours (3-24)</td>
</tr>
<tr>
<td>• 165 positive urine cultures: median time to positivity 16 hours (1-34)</td>
</tr>
</tbody>
</table>

In low risk patients, 6/6 blood cultures, 14/17 urine cultures were positive within 24 hours (no low risk patients had positive CSF).

Source: Kaplan RL
Infants 29-56 Days of Age

Initial ED phase 0-28d

Initial ED phase 29-56d

Inpatient Phase 0-28d

Inpatient Phase 29-56d
### Evidence

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rates of bacterial meningitis in the reviewed studies ranged from 0-1.2%, with the majority (12/15) demonstrating rates less than 0.5%.</td>
</tr>
<tr>
<td>Source: Bachur, Baker, Bonsu, Brik, Paquette, Garcia, Rudinsky, Garra, Pantell, Gomez, Levine, Martinez, Mintegi, Morley, Olaciregui</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients stratified as low risk using a variety of decision rules demonstrate lower rates of bacterial meningitis.</td>
</tr>
<tr>
<td>Source: Bachur, Baker, Baraff, Brik, Paquette</td>
</tr>
</tbody>
</table>
Infants Age 29-56 Days: Initial ED Work-up

Testing for all patients will include:

<table>
<thead>
<tr>
<th>TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood culture</td>
</tr>
<tr>
<td>CBC with diff</td>
</tr>
<tr>
<td>CXR</td>
</tr>
<tr>
<td>(for respiratory symptoms not consistent with bronchiolitis)</td>
</tr>
<tr>
<td>Stool PCR</td>
</tr>
<tr>
<td>(if diarrhea present)</td>
</tr>
<tr>
<td>UA and urine culture</td>
</tr>
</tbody>
</table>

Further management will depend on whether patient is stratified as high or low risk for serious bacterial infection.
Bronchiolitis:

- Can defer CBC and blood culture in patients 29-56d with clinical bronchiolitis and a single fever up to 38.5, if otherwise well appearing.
- Perform CBC, urine culture, and blood culture in patients 29-56d with bronchiolitis with persistent fever (=2 episodes of documented fever ≥ 38).
- Patients with classic features of bronchiolitis who are otherwise well-appearing can be considered “well-appearing” when determining if patient meets low risk criteria.
- Chest X-ray can be deferred if patient has clinical findings consistent with bronchiolitis.
Infants 29-56 Days: ED Management

Low Risk Criteria:

- Well-appearing
- Previously healthy
- Full term (> or = 37 weeks)
- No focal bacterial infection
- Negative urinalysis
- WBC >5,000 and <15,000 mm³
- Absolute bands <1,500 mm³
- No discrete infiltrates on CXR if done
ED Discharge: Low Risk Criteria

Discharge low risk patients if they meet all of the following criteria:

• Feeding well and well appearing
• No social/family concerns
• **Reliable follow-up in 12-24 hours**
• Outpatient plan accepted by PMD and family

A subgroup of low risk patients will not meet discharge criteria. These patients will be admitted without antibiotics for observation.
High Risk of Serious Bacterial Infection:

Patients who do not meet low risk criteria are at higher risk for serious bacterial infection, including meningitis, therefore:

1. Obtain CSF studies (4 tubes)
2. Administer empiric ceftriaxone
3. Admit for empiric antibiotics

**NOTE:** All patients started on empiric antibiotics should receive an LP prior to antibiotic administration, unless they are clinically unstable.
Infants 29-56 Days: Inpatient Management

Admission Criteria:

Low risk patients who do not meet ED discharge criteria will be admitted for observation without antibiotic administration.

Patients with the following will be admitted with empiric antibiotics:

- Ill appearing
- Pre-term (< or = 37 weeks)
- Positive urinalysis
- WBC count < 5,000/mm$^3$ or > 15,000/mm$^3$
- Band count > 1,500/mm$^3$
- Infiltrate on chest x-ray
Empiric Antibiotics:

- Recommend continuing empiric ceftriaxone pending culture results for all patients not meeting low risk criteria (Cincinnati; Gomez B; Morley EJ)
- Ceftriaxone is contraindicated in the following patients:
  - Those with hyperbilirubinemia
  - Those receiving calcium containing IV fluids
Infants 29-56 Days: Inpatient Management

Daily Re-evaluation, if positive culture:

- Treat specific condition (if identified) and transfer to appropriate CSW pathway (UTI, Pneumonia) if applicable
- If LP was not performed at admission, obtain LP prior to starting antibiotics if patient has bacteremia
  - For patients with UTI and negative blood cultures, LP can be deferred
- Narrow antibiotics as appropriate per culture results
Infants 29-56 Days: Inpatient Management

Discharge criteria:

Meet all of the following criteria:

- Well appearing
- Tolerating PO
- **At 36 hours**: if cultures negative and high risk patient (i.e. antibiotics begun)
- **At 24 hours**: if cultures negative and low risk patient (i.e. admitted for observation without antibiotics)
- Adequate follow-up
- PMD and family agree with plan
Information for All Age Groups

Initial ED phase 0-28d

Initial ED phase 29-56d

Inpatient Phase 0-28d

Inpatient Phase 29-56d
Interpreting CSF:

<table>
<thead>
<tr>
<th>CSF Normative Values</th>
<th>Seattle Children’s 2012 Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1 month: CSF WBC &lt;20/mm3</td>
<td>50-60 CSF samples were obtained that met criteria for pleocytosis as defined above</td>
</tr>
<tr>
<td>≥ 1 month: CSF WBC &lt;10/mm3</td>
<td></td>
</tr>
</tbody>
</table>

Initial ED phase 0-28d

Initial ED phase 29-56d

Inpatient Phase 0-28d

Inpatient Phase 29-56d
Interpreting CSF (Cont'd):

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Three studies attempted to define normative CSF values in infants, and found that CSF WBC &gt;16, regardless of whether it was a traumatic tap or not, was a statistical outlier and represented pleocytosis. (Dubos,F)</td>
</tr>
<tr>
<td>Other factors associated with bacterial meningitis were:</td>
</tr>
<tr>
<td>• high protein (&gt;120mg/dL)</td>
</tr>
<tr>
<td>• low glucose(&lt;40mg/dL)</td>
</tr>
<tr>
<td>• neutrophil predominance (&gt;75%)</td>
</tr>
<tr>
<td>An absence of neutrophils makes bacterial meningitis unlikely.</td>
</tr>
<tr>
<td>Source: Bonsu,B.K</td>
</tr>
</tbody>
</table>
Considerations for severely ill patients:

Antibiotics should not be withheld in severely ill patients pending LP.

Goal is for antibiotics to be administered within 60 minutes of presentation.

Inability to obtain CSF

Consider administration of antibiotics and referral to IR for lumbar puncture (LP) for any patient where LP is unsuccessful in the ED.

• Goal is to complete LP and administer antibiotics within 60 minutes of arrival to ED.

Pre-treated CSF:
Consider adding Rapid CSF Bacterial PCR Qual Panel – detects E.coli, Listeria Monocytogenes, Neisseria meningitides, streptococcus agalactiae (Strep B), Streptococcus pneumonia and Haemophilus Influenzae in pre-treated patients with pleocytosis and a concern for bacterial meningitis.
Additional Clinical Considerations

Differential Diagnosis for Severely Ill Febrile Neonate:

- Serious bacterial infection
- HSV
- Varicella zoster virus
- Chlamydia
- Enterovirus
- Adenovirus
Additional Clinical Considerations (Cont'd)

Enterovirus Testing of CSF

Consider CSF Rapid Viral Qual. PCR on all patients with CSF pleocytosis:

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examined the CSF of 361 infants age 56 days or younger and determined that when adjusted for other variables, length of stay is DECREASED by 26% in patients with positive CSF PCRs.</td>
</tr>
</tbody>
</table>

Source: Dewan.M

NOTE: CSF Rapid Viral Qual. PCR Panel will detect HSV 1 & 2, Enterovirus, Human Parechovirus, VZV, CMV, HHV-6. Turn around time is approximately 2 hours and the test is run 24/7.
Additional Clinical Considerations (Cont’d)

Low Risk Criteria – Negative Urinalysis

Definition is consistent with published stratification studies and the CSW UTI pathway:

- <5 WBC/hpf, negative Leukocyte esterase, and negative nitrites
- No bacteria on Gram Stain

<table>
<thead>
<tr>
<th>Seattle Children’s Lab: Situations for Performing Microscopies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any positive result on the reagent strip, with the exception of positive ketones or urobilinogen</td>
</tr>
<tr>
<td>If the dipstick is positive for bilirubin</td>
</tr>
<tr>
<td>Specific request is ordered - e.g. look for cystine crystals</td>
</tr>
<tr>
<td>Unusual color or the drug Mesna in the urine that could interfere with a reagent strip result</td>
</tr>
<tr>
<td>The reagent strip is negative but the urine has an abnormal odor</td>
</tr>
</tbody>
</table>

Initial ED phase 0-28d

Initial ED phase 29-56d

Inpatient Phase 0-28d

Inpatient Phase 29-56d
### Additional Clinical Considerations (Cont'd)

Discharge at 24 hours if Viral Testing Positive:

<table>
<thead>
<tr>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies have shown that patients with bronchiolitis or other viral infections are at lower risk of serious bacterial infections.</td>
</tr>
<tr>
<td>Approximately 90% of bacterial pathogens are identified in the first 24 hours of incubation.</td>
</tr>
<tr>
<td>Consider discharge at 24 hours for all patients who are well-appearing and have a positive (non-HSV) viral study.</td>
</tr>
</tbody>
</table>

Source: Cincinnati

Source: Byington CL
Medical Disclaimer

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.

The authors have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.

However, in view of the possibility of human error or changes in medical sciences, neither the authors nor Seattle Children’s Healthcare System nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information.

Readers should confirm the information contained herein with other sources and are encouraged to consult with their health care provider before making any health care decision.
We used the GRADE method of rating evidence quality. Evidence is first assessed as to whether it is from randomized trial, or observational studies. The rating is then adjusted in the following manner:

Quality ratings are *downgraded* if studies:
- Have serious limitations
- Have inconsistent results
- If evidence does not directly address clinical questions
- If estimates are imprecise OR
- If it is felt that there is substantial publication bias

Quality ratings can be *upgraded* if it is felt that:
- The effect size is large
- If studies are designed in a way that confounding would likely underreport the magnitude of the effect OR
- If a dose-response gradient is evident

**Quality of Evidence:**
- ★★★★★ High quality
- ★★★★☆ Moderate quality
- ★★★☆☆ Low quality
- ★★☆☆☆ Very low quality
- ★☆☆☆☆ Expert Opinion (E)

Literature searches were conducted in two phases: May and August of 2018. The initial search targeted synthesized literature on neonatal fever. The second search targeted primary or synthesized literature in two ways: (1) fever or meningococcal infections combined with bronchiolitis, influenza, respirovirus, or respiratory syncytial virus; or (2) spinal taps. All literature was limited to neonates. The initial search was limited to January 2012 to date, and the second search was limited to January 2015 to date. Searches were run using controlled subject headings where available, and text words in the following databases: Ovid MEDLINE, Cochrane Database of Systematic Reviews, EMBASE, National Guidelines Clearinghouse, and Transforming Research into Practice (TRIP).

Flow diagram adapted from Moher D et al. BMJ 2009;339:bmj.b2535
Summary of Version Changes

- **Version 1.0 (8/13/2013):** Go live
- **Version 1.1 (9/5/2013):** Clarified maternal risk factors for HSV and decision to test for neonatal HSV
- **Version 2.0 (2/26/2016):** Addition of the Neonatal Fever (31-60 days) with Bronchiolitis ED Phase
- **Version 3.0 (2/21/2017):** Modification of HSV management (0-30 days)
- **Version 4.0 (9/11/2017):** Modification- Guidance on inability to obtain CSF and fever at home
- **Version 5.0 (1/7/2019):** Periodic update that included the modification change of the inclusion criteria to 0-28 days and 29-56 days. Updated antibiotic choices for the inpatient phase of 0-28 days
- **Version 6.0 (8/16/2019):** Updated CHILD site and slides to match 29-56 day low risk criteria on algorithm
- **Version 7.0 (12/22/2021):** Removed HSV DFA/Culture guidance from pathway.
- **Version 8.0 (1/12/2022):** Updated the recommendation for swabbing on page 11 (Infants 0-28 Days: HSV- Complete HSV Work-up) from 1 swab to 3 swabs pooled in one media.
Approved by the CSW Neonatal Fever for January 8, 2019

CSW Neonatal Fever Team:

Pathway Owner, Hospital Medicine: Julianne Bishop, MD
Pathway Owner, Emergency: Heath Stanford Ackley, MD
Clinical Nurse Specialist, Medical Unit: Ellie McMahon, RN
Clinical Nurse Specialist, Emergency: Sara Fenstermacher, MN, RN

Clinical Effectiveness Team:

Consultant: Sara Vora, MD MPH
Project Manager: Asa Herrman
CE Analyst: James Johnson
CIS Informatician: Carlos Villavicencio, MD, MMI
CIS Analyst: Maria Jerome, Julia Hayes
Librarian: Peggy Cruse
Program Coordinator: Kristyn Simmons

Clinical Effectiveness Leadership:

Medical Director: Darren Migita, MD
Operations Director: Karen Rancich Demmert, BS, MA

Retrieval Website: https://www.seattlechildrens.org/pdf/neonatal-fever-pathway.pdf

Please cite as: